Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Meibomian Gland Dysfunction

29 trials tracked for Meibomian Gland Dysfunction: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 33 citations.

29Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 8 Other / NA 18
  1. Phase 4 Intraductal Meibomian Gland Probing Trial Completed · 33 cited
  2. Phase 4 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis Completed
  3. Phase 3 Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD) Completed
  4. Phase 2 Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction Completed
  5. Phase 2 Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction Completed
  6. Phase 2 Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction Completed
Show 23 more trials
  1. Phase 2 Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction Completed
  2. Phase 2 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction Completed
  3. Phase 2 A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Completed
  4. Phase 2 Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD Completed
  5. Phase 2 Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) Completed
  6. N/A Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers Completed
  7. N/A Meibography and Tear Scan Using the Oculus Keratograph 4 Completed
  8. N/A to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction Completed
  9. N/A Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers Completed
  10. N/A The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction Completed
  11. N/A Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction Completed
  12. N/A Tear Film Innovations iLux Safety Study Completed
  13. N/A Meibomian Gland Dysfunction Treatment Completed
  14. N/A Evaluation of the LipiFlow System With a New Activator Completed
  15. N/A Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime Completed
  16. N/A Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction Completed
  17. N/A Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study Completed
  18. N/A Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction Completed
  19. N/A Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye Completed
  20. N/A TearCare System to Treat Dry Eye Disease Completed
  21. N/A Mechanisms of Light-based Therapies for Dry Eye Disease Completed
  22. N/A Contact Lens Comfort Relative to Meibomian Gland Status Completed
  23. N/A Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Incomplete nasolacrimal duct obstruction associated with severe upper eyelid meibomian gland loss
Rheumatology Cohort
Incomplete nasolacrimal duct obstruction associated with severe upper eyelid meibomian gland loss Incomplete blockage drives severe gland loss in postmenopausal women
This prospective cross-sectional study of 272 postmenopausal women found an association between incomplete nasolacrimal duct obstruction and…
A partial blockage in the tear duct causes much worse eye gland damage than a complete blockage in postmenopausal women.
Frontiers Apr 30, 2026
Perfluorohexyloctane Improves DED Symptoms in MGD Patients with Varied Baseline Severity
Drug Pipeline RCT
Perfluorohexyloctane Improves DED Symptoms in MGD Patients with Varied Baseline Severity Could new eye drops really ease dry eye symptoms for many patients?
Perfluorohexyloctane showed higher odds of improving EDS (OR: 2.25) and tCFS (OR: 2.21) in DED with MGD. Safety was consistent across severi…
New eye drops helped patients with severe dry eye feel better and improved their eye health more than saline, with few side effects.
Mar 28, 2026